Water Res
Jiangsu Province Center for Disease Control and Prevention, Nanjing 210009 Jiangsu, China. Electronic address:
Published: March 2025
Cardiovascular pharmaceuticals were extensively detected and generally coexist with their transformation products (TPs) in wastewater. However, knowledges on TPs and transformation processes for cardiovascular pharmaceuticals remained largely unclear. To fill this knowledge gap, nontarget screening combined with batch experiments were employed to reveal the transformation of five cardiovascular pharmaceuticals (atenolol, metoprolol, propranolol, bezafibrate and candesartan) in aerobic activated sludge. The removal rate constants per unit of biomass ranged from 0.0105 to 0.0571 L g SS h for five cardiovascular pharmaceuticals. Atenolol and bezafibrate exhibited more excellent removal efficiency (over 99 %) than other three cardiovascular pharmaceuticals. Subsequently, 33 TPs were tentatively identified and 16 of them were not reported in previous studies. Based on identified TPs, transformation pathways of five cardiovascular pharmaceuticals were proposed, which suggested acetylation, ammoniation, carboxylation, dealkylation, decarboxylation, dihydroxylation, demethylation, epoxidation, formylation, hydrogenation, hydrolysis, hydroxylation, methylation and oxidation were involved in the transformation of cardiovascular pharmaceuticals in wastewater. Notably, N- dealkylation at the site of secondary and tertiary amine, acetylation at the site of primary amine and dehydrogenation at the site of linear alkyl were summarized as the specific transformation patterns across different cardiovascular pharmaceuticals. Furthermore, the predicted results suggested that about 30 % TPs have higher persistence and bioaccumulation than parent compounds while about 40 % TPs harbored higher toxicity than parent compounds of cardiovascular pharmaceuticals. Collectively, this study unveiled the fate and transformation pathways of five cardiovascular pharmaceuticals and summarized the specific transformation patterns for them in aerobic activated sludge, which is theoretically useful to effectively remove pharmaceuticals from wastewater.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.watres.2025.123425 | DOI Listing |
Int J Hematol
March 2025
Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-αβ integrin antibody vedolizumab showed greater efficacy than placebo for prevention of lower-gastrointestinal (GI) acute graft-versus-host disease (aGVHD) after unrelated allogenic hematopoietic stem cell transplantation (allo-HSCT). This post hoc analysis assessed the efficacy and safety of vedolizumab versus placebo for lower-GI aGVHD prevention in Japanese and non-Japanese patients, when added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate/mycophenolate mofetil + / - anti-thymocyte globulin [ATG]). The analysis included 35 (18 vedolizumab-treated, 17 placebo-treated) Japanese and 298 (150 vedolizumab-treated, 148 placebo-treated) non-Japanese patients.
View Article and Find Full Text PDFIntern Emerg Med
March 2025
Department of General Medicine, Okayama City Hospital, Okayama, Japan.
Basic Res Cardiol
March 2025
Cardiovascular and Metabolic Disorders Programme, Duke-NUS Medical School, 8 College Road, Singapore, Singapore.
Although many cardioprotective interventions have been shown to limit infarct size (IS), in preclinical animal studies of acute myocardial ischemia/reperfusion injury (IRI), their clinical translation to patient benefit has been largely disappointing. A major factor is the lack of rigor and reproducibility in the preclinical studies. To address this, we have established the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) small animal multisite acute myocardial infarction (AMI) network, with centralized randomization and blinded core laboratory IS analysis, and have validated the network using ischemic preconditioning (IPC).
View Article and Find Full Text PDFJAMA Cardiol
March 2025
Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Importance: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.
Objective: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.
Emerg Microbes Infect
March 2025
Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
The emergence of carbapenem-resistant (CREC) poses crucial challenges in clinical management, requiring continuous monitoring to inform control and treatment strategies. This study aimed to investigate the genomic and epidemiological characteristics of CREC isolates obtained from a tertiary hospital in China between 2015 and 2022. Next-generation sequencing was used for genomic profiling, and clinical data from patients were integrated into the analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.